Xanthine oxidoreductase-IN-3
Modify Date: 2024-04-06 09:35:50
Xanthine oxidoreductase-IN-3 structure
|
Common Name | Xanthine oxidoreductase-IN-3 | ||
|---|---|---|---|---|
| CAS Number | 651769-78-7 | Molecular Weight | 299.71500 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H10ClN5O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Xanthine oxidoreductase-IN-3Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia[1]. |
| Name | N-(4-chlorophenyl)-4-(2H-tetrazol-5-yl)benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | Xanthine oxidoreductase-IN-3 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 26.3 nM. Xanthine oxidoreductase-IN-3 can be used for the research of acute hyperuricemia[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 26.3 nM (xanthine oxidoreductase)[1] |
| In Vivo | Xanthine oxidoreductase-IN-3 (化合物 IIIa) (5 mg/kg; 口服给药) 在给药后 3 h 显示出降低急性高尿酸血症小鼠尿酸的作用[1]。 Animal Model: ICR mice (18-22 g) were induced acute hyperuricemia by injection of potassium oxonate and hypoxanthine[1] Dosage: 5 mg/kg Administration: Suspended in 0.5% CMC-Na solution for intragastric administration Result: Showed a uric acid-lowering effect from 3 h after administration. |
| References |
| Molecular Formula | C14H10ClN5O |
|---|---|
| Molecular Weight | 299.71500 |
| Exact Mass | 299.05700 |
| PSA | 87.05000 |
| LogP | 3.15640 |
| Benzamide,N-(4-chlorophenyl)-4-(1H-tetrazol-5-yl) |